Erythroderma Diagnosis and Management

Initial Assessment and Stabilization

The American Academy of Dermatology recommends beginning immediate supportive care with wet dressings using mid-potency topical steroids, strict attention to fluid balance with control of ankle edema, and rule out sepsis with blood cultures before initiating definitive therapy 1
Complete blood count with differential, liver and kidney function tests, electrolytes, glucose, coagulation studies, and inflammatory markers should be performed to assess the patient's condition 2, 3
Blood cultures should be taken if the patient is febrile to exclude sepsis 2, 3
A chest X-ray should be performed to assess for pulmonary involvement 3
Baseline body weight and vital signs with pulse oximetry should be recorded 3
The percentage of body surface area involved should be documented using the Lund and Browder chart 3

The British Journal of Dermatology suggests obtaining multiple skin biopsies from different sites to enhance diagnostic accuracy when the etiology is uncertain 3
For psoriatic erythroderma, look for indurated plaques with silvery scale, personal or family history of psoriasis, lack of "skip" areas, and absence of significant palmoplantar keratoderma 4, 5, 6
For cutaneous T-cell lymphoma/Sézary syndrome, obtain blood for flow cytometry, Sézary cell count, and T-cell receptor gene rearrangement clonality; look for atypical lymphocytes on biopsy 4, 5
For pityriasis rubra pilaris, presence of "skip" areas, significant palmoplantar keratoderma, and islands of sparing are characteristic 4, 5
A detailed medication history should be taken to investigate potential drug-induced erythroderma 3
HIV screening may be useful as HIV can present as erythroderma 4, 5

The American Academy of Dermatology recommends applying wet dressings with mid-potency topical corticosteroids to all affected areas 1
Aggressive emollient therapy with petrolatum-based ointments should be applied liberally 2, 7
Establish peripheral venous access through non-lesional skin when possible and commence IV fluid resuscitation if clinically indicated 3
Insert a nasogastric tube and institute feeding if the patient cannot maintain adequate oral hydration and nutrition 3
For systemically ill patients with erythrodermic psoriasis, oral cyclosporine 3-5 mg/kg/day is a logical first choice due to its rapid onset of action 1, 4
Acitretin, biologic agents, cyclosporine, and methotrexate are first-line systemic options for erythrodermic psoriasis 1
Combination therapy with acitretin and cyclosporine, acitretin and TNF blocker, cyclosporine and methotrexate, or methotrexate and TNF blocker may be considered 1

Treatment decisions should favor options that act quickly and have more predictable responses, with specific systemic therapy based on short-term efficacy rather than long-term results or potential side effects 4, 5
After acute illness improves, transition to therapies more appropriate for longer-term maintenance 4
Taper cyclosporine and discontinue over ensuing 2 months while introducing maintenance biologic therapy 1

If Stevens-Johnson syndrome, toxic epidermal necrolysis, or DRESS is suspected with any mucous membrane involvement, immediately discontinue all potential culprit drugs and consult dermatology 2, 7
For Grade 3-4 SCAR, admit immediately to burn unit or ICU with dermatology and wound care consultation 2, 7
Initiate IV methylprednisolone 1-2 mg/kg, converting to oral steroids when appropriate and tapering over at least 4 weeks 2, 7
Consider IVIG or cyclosporine in severe or steroid-unresponsive cases 2
Permanently discontinue immune checkpoint inhibitor if applicable 2

Never use systemic corticosteroids as monotherapy in psoriatic erythroderma, as abrupt discontinuation can trigger severe flares including potentially life-threatening generalized pustular psoriasis or erythrodermic exacerbations 8
Avoid trimethoprim-sulfa antibiotics in patients on methotrexate due to drug interactions 1
Do not delay admission to burn center if mucous membrane involvement or blistering is noted 2, 7
Avoid long-term systemic corticosteroids; transition to steroid-sparing options when possible 2, 7
Monitor for secondary bacterial infection but avoid prophylactic antibiotics unless clinically indicated 1

Reassess every 2-3 days for progression or improvement 2, 7
Screen patients treated with biologics similarly to other biologic agents per standard protocols 5, 6